Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas

Xiaomin Liu, Hideyuki Kano, Douglas Kondziolka, Kyung-Jae Park, Aditya Iyer, Samuel Shin, Ajay Niranjan, John C. Flickinger, L. Dade Lunsford

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We evaluated the efficacy of Gamma knife stereotactic radiosurgery (GKSR) as an adjunctive management modality for patients with drug resistant or intolerant cavernous sinus invasive prolactinomas. Twenty-two patients with cavernous sinus invasive prolactinoma underwent GKSR between 1994 and 2009. Thirteen patients were dopamine agonist (DA) resistant. Six patients were intolerant to DA. Three patients chose GKSR as their initial treatment modality in hopes they might avoid life long suppression medication. The median tumor volume was 3.0 cm3 (range 0.3-11.6). The marginal tumor dose (median = 15 Gy, range 12-25 Gy) prescribed was based on the dose delivered to the optic apparatus. The median follow-up interval was 36 months (range, 12-185). Endocrine normalization was defined as a normal serum prolactin level off DA (cure) or on DA. Endocrine improvement was defined as a decreased but still elevated serum prolactin level. Endocrine deterioration was defined as an increased serum prolactin level. Endocrine normalization was achieved in six (27.3%) patients. Twelve (54.5%) patients had endocrine improvement. Four patients (18.2%) developed delayed increased prolactin. Imaging-defined local tumor control was achieved in 19 (86.4%) patients, 12 of whom had tumor regression. Three patients had a delayed tumor progression and required additional management. One patient developed a new pituitary axis deficiency after GKSR. Invasive prolactinomas continue to pose management challenges. GKSR is a non invasive adjunctive option that may reduce prolactin levels in patients who are resistant to or intolerant of suppression medication. In a minority of cases, patients may no longer require long term suppression therapy.

Original languageEnglish
Pages (from-to)68-75
Number of pages8
JournalPituitary
Volume16
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Prolactinoma
Radiosurgery
Pharmaceutical Preparations
Prolactin
Dopamine Agonists
Cavernous Sinus
Neoplasms
Serum
Tumor Burden

Keywords

  • Cavernous sinus
  • Gamma knife
  • Pituitary adenoma
  • Prolactinoma
  • Radiosurgery

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. / Liu, Xiaomin; Kano, Hideyuki; Kondziolka, Douglas; Park, Kyung-Jae; Iyer, Aditya; Shin, Samuel; Niranjan, Ajay; Flickinger, John C.; Lunsford, L. Dade.

In: Pituitary, Vol. 16, No. 1, 01.01.2013, p. 68-75.

Research output: Contribution to journalArticle

Liu, X, Kano, H, Kondziolka, D, Park, K-J, Iyer, A, Shin, S, Niranjan, A, Flickinger, JC & Lunsford, LD 2013, 'Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas', Pituitary, vol. 16, no. 1, pp. 68-75. https://doi.org/10.1007/s11102-012-0376-x
Liu, Xiaomin ; Kano, Hideyuki ; Kondziolka, Douglas ; Park, Kyung-Jae ; Iyer, Aditya ; Shin, Samuel ; Niranjan, Ajay ; Flickinger, John C. ; Lunsford, L. Dade. / Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. In: Pituitary. 2013 ; Vol. 16, No. 1. pp. 68-75.
@article{4e8ce97f1fd4477f839b8803e153c123,
title = "Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas",
abstract = "We evaluated the efficacy of Gamma knife stereotactic radiosurgery (GKSR) as an adjunctive management modality for patients with drug resistant or intolerant cavernous sinus invasive prolactinomas. Twenty-two patients with cavernous sinus invasive prolactinoma underwent GKSR between 1994 and 2009. Thirteen patients were dopamine agonist (DA) resistant. Six patients were intolerant to DA. Three patients chose GKSR as their initial treatment modality in hopes they might avoid life long suppression medication. The median tumor volume was 3.0 cm3 (range 0.3-11.6). The marginal tumor dose (median = 15 Gy, range 12-25 Gy) prescribed was based on the dose delivered to the optic apparatus. The median follow-up interval was 36 months (range, 12-185). Endocrine normalization was defined as a normal serum prolactin level off DA (cure) or on DA. Endocrine improvement was defined as a decreased but still elevated serum prolactin level. Endocrine deterioration was defined as an increased serum prolactin level. Endocrine normalization was achieved in six (27.3{\%}) patients. Twelve (54.5{\%}) patients had endocrine improvement. Four patients (18.2{\%}) developed delayed increased prolactin. Imaging-defined local tumor control was achieved in 19 (86.4{\%}) patients, 12 of whom had tumor regression. Three patients had a delayed tumor progression and required additional management. One patient developed a new pituitary axis deficiency after GKSR. Invasive prolactinomas continue to pose management challenges. GKSR is a non invasive adjunctive option that may reduce prolactin levels in patients who are resistant to or intolerant of suppression medication. In a minority of cases, patients may no longer require long term suppression therapy.",
keywords = "Cavernous sinus, Gamma knife, Pituitary adenoma, Prolactinoma, Radiosurgery",
author = "Xiaomin Liu and Hideyuki Kano and Douglas Kondziolka and Kyung-Jae Park and Aditya Iyer and Samuel Shin and Ajay Niranjan and Flickinger, {John C.} and Lunsford, {L. Dade}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/s11102-012-0376-x",
language = "English",
volume = "16",
pages = "68--75",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas

AU - Liu, Xiaomin

AU - Kano, Hideyuki

AU - Kondziolka, Douglas

AU - Park, Kyung-Jae

AU - Iyer, Aditya

AU - Shin, Samuel

AU - Niranjan, Ajay

AU - Flickinger, John C.

AU - Lunsford, L. Dade

PY - 2013/1/1

Y1 - 2013/1/1

N2 - We evaluated the efficacy of Gamma knife stereotactic radiosurgery (GKSR) as an adjunctive management modality for patients with drug resistant or intolerant cavernous sinus invasive prolactinomas. Twenty-two patients with cavernous sinus invasive prolactinoma underwent GKSR between 1994 and 2009. Thirteen patients were dopamine agonist (DA) resistant. Six patients were intolerant to DA. Three patients chose GKSR as their initial treatment modality in hopes they might avoid life long suppression medication. The median tumor volume was 3.0 cm3 (range 0.3-11.6). The marginal tumor dose (median = 15 Gy, range 12-25 Gy) prescribed was based on the dose delivered to the optic apparatus. The median follow-up interval was 36 months (range, 12-185). Endocrine normalization was defined as a normal serum prolactin level off DA (cure) or on DA. Endocrine improvement was defined as a decreased but still elevated serum prolactin level. Endocrine deterioration was defined as an increased serum prolactin level. Endocrine normalization was achieved in six (27.3%) patients. Twelve (54.5%) patients had endocrine improvement. Four patients (18.2%) developed delayed increased prolactin. Imaging-defined local tumor control was achieved in 19 (86.4%) patients, 12 of whom had tumor regression. Three patients had a delayed tumor progression and required additional management. One patient developed a new pituitary axis deficiency after GKSR. Invasive prolactinomas continue to pose management challenges. GKSR is a non invasive adjunctive option that may reduce prolactin levels in patients who are resistant to or intolerant of suppression medication. In a minority of cases, patients may no longer require long term suppression therapy.

AB - We evaluated the efficacy of Gamma knife stereotactic radiosurgery (GKSR) as an adjunctive management modality for patients with drug resistant or intolerant cavernous sinus invasive prolactinomas. Twenty-two patients with cavernous sinus invasive prolactinoma underwent GKSR between 1994 and 2009. Thirteen patients were dopamine agonist (DA) resistant. Six patients were intolerant to DA. Three patients chose GKSR as their initial treatment modality in hopes they might avoid life long suppression medication. The median tumor volume was 3.0 cm3 (range 0.3-11.6). The marginal tumor dose (median = 15 Gy, range 12-25 Gy) prescribed was based on the dose delivered to the optic apparatus. The median follow-up interval was 36 months (range, 12-185). Endocrine normalization was defined as a normal serum prolactin level off DA (cure) or on DA. Endocrine improvement was defined as a decreased but still elevated serum prolactin level. Endocrine deterioration was defined as an increased serum prolactin level. Endocrine normalization was achieved in six (27.3%) patients. Twelve (54.5%) patients had endocrine improvement. Four patients (18.2%) developed delayed increased prolactin. Imaging-defined local tumor control was achieved in 19 (86.4%) patients, 12 of whom had tumor regression. Three patients had a delayed tumor progression and required additional management. One patient developed a new pituitary axis deficiency after GKSR. Invasive prolactinomas continue to pose management challenges. GKSR is a non invasive adjunctive option that may reduce prolactin levels in patients who are resistant to or intolerant of suppression medication. In a minority of cases, patients may no longer require long term suppression therapy.

KW - Cavernous sinus

KW - Gamma knife

KW - Pituitary adenoma

KW - Prolactinoma

KW - Radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84873732926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873732926&partnerID=8YFLogxK

U2 - 10.1007/s11102-012-0376-x

DO - 10.1007/s11102-012-0376-x

M3 - Article

C2 - 22302560

AN - SCOPUS:84873732926

VL - 16

SP - 68

EP - 75

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 1

ER -